Trials / Completed
CompletedNCT02651194
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-493/ABT-530 | Tablet; ABT-493 coformulated with ABT-530 |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-10-01
- Completion
- 2017-01-01
- First posted
- 2016-01-08
- Last updated
- 2017-10-16
- Results posted
- 2017-10-16
Source: ClinicalTrials.gov record NCT02651194. Inclusion in this directory is not an endorsement.